Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

The novel Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated patients relapse with resistance and fulminant progression. Using chemical proteomics and an organotypic cell-based drug screening assa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Zhao, Xiaohong, Lwin, Tint, Silva, Ariosto, Shah, Bijal, Tao, Jiangchuan, Fang, Bin, Zhang, Liang, Fu, Kai, Bi, Chengfeng, Li, Jiannong, Jiang, Huijuan, Meads, Mark B., Jacobson, Timothy, Silva, Maria, Distler, Allison, Darville, Lancia, Zhang, Ling, Han, Ying, Rebatchouk, Dmitri, Di Liberto, Maurizio, Moscinski, Lynn C., Koomen, John M., Dalton, William S., Shain, Kenneth H., Wang, Michael, Sotomayor, Eduardo, Tao, Jianguo
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399304/
https://ncbi.nlm.nih.gov/pubmed/28416797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms14920
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados